Implementation of the new biosimilars policy in British Columbia
Earlier this year, British Columbia PharmaCare announced a new biosimilars initiative which introduced changes to its coverage for REMICADE® (infliximab), ENBREL® (etanercept) and LANTUS® (insulin glargine). This initiative is intended to switch PharmaCare patients with certain medical conditions, from originator biologic drugs to their biosimilar versions. Biosimilars are just as safe and effective as the originator biologics, but are less expensive.
Impact on iA Financial Group plan members in British Columbia
iA Financial Group welcomes BC’s biosimilars initiative as it aligns with our efforts to provide comprehensive drug plans at a sustainable cost for group insurance plan members and sponsors across Canada. Therefore, iA Financial Group is aligning adjudication for targeted biologics as closely as possible with the new BC biosimilars policy.
Personalized communication to current claimants for REMICADE®, ENBREL® and LANTUS®
At iA Financial Group, the well-being of plan members is at the center of our philosophy. Therefore, in the coming weeks, we will individually contact affected claimants to offer support and assistance in the transition to the biosimilar drug, in collaboration with their prescribers. Nonetheless, we will explore coverage solutions for whom the switch may not be advisable.
If you have any questions, please contact your advisor or your iA Financial Group Account Executive.